Clinical Assessment Methods Flashcards

A 68-year-old patient on warfarin presents with an INR of 4.9. She reports no active bleeding but mentions she started a new herbal supplement two weeks ago. On assessment, you note petechiae on her forearms and mild epistaxis that resolved spontaneously yesterday. Which clinical assessment finding most directly changes your immediate management decision?

Answer: Spontaneously resolved epistaxis with petechiae indicating minor mucocutaneous bleeding requiring dose hold only

The combination of petechiae and spontaneously resolved epistaxis constitutes minor bleeding. Canadian guidelines (and CHEST) classify this as minor mucocutaneous bleeding with supratherapeutic INR: the recommendation is to withhold warfarin dose(s) and recheck INR within 24–48 hours — not to administer vitamin K or FFP unless INR >10 or major/life-threatening bleeding is present. FFP is reserved for life-threatening hemorrhage. Petechiae in this context reflect elevated INR-related capillary fragility, not a primary platelet disorder.

During a medication review, a pharmacist uses the Beers Criteria and STOPP/START tool concurrently on the same 78-year-old patient. The Beers Criteria flags a medication that STOPP/START does NOT flag. Which statement best explains the most clinically significant reason these tools can diverge in their findings?

Answer: Beers Criteria is developed for the U.S. population and may flag drugs not available or studied in the Canadian/European context addressed by STOPP/START

The Beers Criteria is developed by the American Geriatrics Society and is U.S.-centric, sometimes flagging drugs (e.g., certain antihistamines, muscle relaxants, or formulations) that differ in availability, evidence base, or clinical context compared to STOPP/START, which was developed in Europe and validated in European/Canadian settings. Both tools address pharmacokinetic and pharmacodynamic changes; neither requires a minimum drug count; and both can be applied across care settings. The geographic/formulary divergence is the most recognized reason for discordant flagging.

A pharmacist conducts a comprehensive medication review using the SOAP format. In the 'Assessment' section for a patient with poorly controlled type 2 diabetes (A1C 10.2%), the pharmacist notes: 'Patient non-adherent due to cost barriers; metformin dose subtherapeutic at 500 mg daily; no SGLT2 inhibitor despite ASCVD.' Which element, if absent from this Assessment section, would most compromise the clinical utility of the note for a collaborating prescriber?

Answer: A prioritized problem list distinguishing drug therapy problems by type (unnecessary drug, wrong dose, needs additional therapy)

The pharmacist-specific value-add in an Assessment section is classifying drug therapy problems (DTPs) by category — e.g., 'needs additional drug therapy' (no SGLT2i despite ASCVD indication), 'dosage too low' (metformin 500 mg), and 'adherence' (cost-related). Without this DTP taxonomy, the Assessment lacks actionable clinical structure and becomes indistinguishable from a nursing or physician note. Restating objective data, including verbatim subjective accounts, or repeating med lists from prior sections does not enhance the Assessment's clinical utility — it creates redundancy.

A 55-year-old man with schizophrenia on clozapine 400 mg/day presents to the pharmacy. His caregiver reports new-onset nocturnal enuresis, excessive drooling, and constipation over the past 3 weeks, with no changes to his regimen. On assessment, the pharmacist notes a resting heart rate of 112 bpm and temperature of 37.0°C. Which assessment interpretation is MOST accurate?

Answer: The symptom cluster is consistent with clozapine-induced autonomic effects: sialorrhea and enuresis from muscarinic agonism, constipation from anticholinergic effects, and tachycardia from alpha-1 blockade — not a toxidrome

Clozapine has paradoxical autonomic effects: despite being highly anticholinergic at some receptors (causing constipation), it is also a muscarinic M4 agonist — producing sialorrhea (drooling) and nocturnal enuresis. Alpha-1 blockade causes reflex tachycardia. This combination is a recognized, non-emergent side effect profile not representing toxicity or NMS (which requires hyperthermia, rigidity, and altered consciousness). Myocarditis workup is indicated for new-onset tachycardia with fever/dyspnea early in treatment (typically within 4–6 weeks of initiation), not for stable patients with 3 weeks of these specific symptoms. NMS requires rigidity and elevated temperature (>38°C), absent here.

A pharmacist assessing pain using a validated tool selects the CPOT (Critical-Care Pain Observation Tool) over the NRS (Numeric Rating Scale 0–10) for a post-operative patient. Which patient characteristic makes the CPOT the most appropriate selection?

Answer: The patient is intubated and mechanically ventilated in the ICU, precluding self-report

The CPOT is a behavioural pain assessment tool specifically validated for use in critically ill, mechanically ventilated, non-verbal patients who cannot self-report pain. It scores facial expression, body movements, muscle tension, and compliance with the ventilator. The NRS requires verbal or numerical self-report — impossible in an intubated patient. Language barriers are managed through interpreter services, not by switching to a behavioural tool. A history of opioid use disorder does not invalidate self-report; patients with OUD can still use NRS. Mild cognitive impairment in older adults may warrant tools like the PAINAD scale, not specifically CPOT.

A community pharmacist is performing a structured adherence assessment using pill counts supplemented by pharmacy refill records (MPR calculation). The patient's MPR for their antihypertensive is 0.93 over 12 months, yet their BP remains uncontrolled at 158/96 mmHg at every visit. Which phenomenon MOST likely accounts for this discrepancy and should be documented in the pharmacist's assessment?

Answer: The 'white-coat' or 'parking-lot' adherence effect: the patient fills prescriptions regularly but takes medication selectively, with clustering of doses around refill or clinic dates

MPR and pill counts are indirect adherence measures — they capture possession and dispensing, not actual ingestion. 'White-coat adherence' (also called 'toothbrush adherence' or adherence clustering) is well-documented: patients who are otherwise non-adherent increase pill-taking days before clinic visits or refill dates, producing artificially high MPR values while maintaining subtherapeutic drug exposure between those windows. This explains how MPR ≥0.90 can coexist with consistently uncontrolled BP. Documenting this pattern is critical before escalating therapy — dose increases in a non-adherent patient are ineffective and potentially harmful. Direct measures (e.g., drug urine/blood levels, electronic pill caps) are needed to confirm.